Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI,Feb. 28,2023 -- Oricell Therapeutics Co.,Ltd ("Oricell" or "the Company"),a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics,today announced the close of a $45M Series B1 investment round after the completion of a $125M Series B fund-raise in July 2022. The round was led by premier global industry investors RTW Investments,LP ("RTW") and Qatar Investment Authority ("QIA"),with participation from existing investors,including Qiming Venture Partners and C&D Emerging Industry Equity Investment. The new injection of capital will be utilized primarily to support the company's core product clinical development in the U.S.

Oricell Chairman and CEO Helen Yang said,"We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further expand our platform and research. This round reflects our investors' recognition of Oricell's ongoing growth and the development of our robust pipeline of ground-breaking therapeutics. We look forward to continuing to help improving the lives of patients in need."

Over the past year,Oricell's cell therapy pipeline and drug discovery platform have seen tremendous growth. Since the debut of Oricell's first key product Ori-C101 at the 2021 American Society of Clinical Oncology ("ASCO") Annual Meeting,the Company has been overcoming many difficulties and made unremitting efforts to achieve all the expected milestones,to attract widespread attention among investors worldwide with its increased presence in the global new drug market during 2022 and into 2023. The Company launched its red-chip restructuring in the fourth quarter of last year in parallel with series B round of financing. Ori-C101 received IND clearance from NMPA in September 2022. At 2022 ASCO annual meeting and European Hematology Association ("EHA") 2022 congress,Oricell presented the clinical research data of its proprietary CAR-T cell therapy targeting GPRC5D (OriCAR-017) for the treatment of Relapsed/Refractory Multiple Myeloma ("RRMM"). The oral presentation was very well received; subsequently,the product was granted an orphan drug designation by US FDA. Its follow-up data was published in Lancet Haematology on January 31 2023.

With this new funding,the Company is now well-positioned to expand its products to the U.S.,specifically OriCAR-017,a GPRC5D CAR-T therapeutic that treats relapsed and refractory multiple myeloma,which is a product currently on the stage of IND enabling both in the US and China.

Roderick Wong,M.D.,Managing Partner and Chief Investment Officer of RTW,said"RTWcontinues to focus on advanced tumor cellular immunotherapeutics. As a long-term investor in the primary and secondary markets,we have been closely following Oricell and have been duly impressed by its milestone achievements over the past year. Today,we feel honored to have established a partnership with the company through the Series B1 financing. With our years of experience working in the U.S. market,we look forward to empowering Oricell and its team as they continue to provide cancer patients across the world with better therapies and create more value for the community."

About RTW Investment

Headquartered in New York,with offices in Shanghai and London,RTW Investments,LP is a global life sciences investment and innovation firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia,RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building and supporting the companies and/or academics developing them. For further information about RTW,please visit www.rtwfunds.com

About Qatar Investment Authority

Qatar Investment Authority ("QIA") is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar.

About Qiming Venture Partners

Founded in 2006,Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai,Beijing,Suzhou,Hong Kong,Seattle,Boston and the San Francisco Bay Area. Currently,Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment,we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

About C&D Emerging Industry Equity Investment

Xiamen C&D Emerging Industry Equity Investment Co.,Ltd is a professional equity asset management company affliated to Xiamen C&D Corporation Limited,focusing on new economy sectors including healthcare,advanced manufacturing and innovative consumption.

The subsidiary manages a fund of RMB18 billion to help more emerging enterprises flourish.

About Oricell Therapeutics

Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Oricell has applied for over 100 invention patents (including 6 PCT),with 10 already granted.

Oricell Therapeutics' mission is to develop affordable drugs for unmet clinical needs worldwide. It has built several proprietary technology platforms based on tumor cell immunotherapy,including Ori®Ab and Ori®CAR. Oricell Therapeutics has made several achievements to overcome challenges to treat solid tumors including among others antibody engineering construction technology,tumor immune microenvironment regulation,T cell infiltration and killing ability.

With over 10 cellular projects in its pipeline,Oricell Therapeutics is well positioned to develop novel cell therapies to treat liquid and solid tumors. Oricell focuses on indications with a wide range of therapeutic needs,including liver,ovarian,gastric,cervical and non-small cell lung cancer,as well as multiple myeloma. With the corporate goal of becoming an innovation-driven global leader in the creation of new tumor immunotherapeutics,Oricell Therapeutics has established an international product development and operations management team,GMP-compliant manufacturing facilities and quality testing and management systems. Oricell Therapeutics is continuing to explore and develop therapeutically effective,well differentiated and affordable drugs through its own innovative technology platforms. The company seeks to create new opportunities for the development of innovative China-made drugs. Oricell raised over $120 million USD in series B financing in July 2022.

View original content:https://www.prnewswire.com/news-releases/oricell-closes-45m-series-b1-financing-to-expand-development-of-key-products-301756385.html